Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Oncolysin B data

IMGN presented Phase I/II and Phase II trial results after ABMT, showing that 10 of 12 patients in the initial trial

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE